Clin Cancer Res: The efficacy of anti-colony stimulating factor monoclonal antibody Lacnotuzumab combined with gemcitabine-carboplatin in the treatment of triple-negative breast cancer

Triple negative breast cancer (TNBC) accounts for approximately 15% to 20% of all breast cancers
.

According to the American Society of Clinical Oncology / College of American Pathologists guidelines, TNBC definition: by immunoassay was used to detect estrogen receptor (ER) and progesterone receptors (PgR) expression% and ≤1

Breast cancer immunity

In this study, a phase II clinical trial designed to clear gemcitabine in patients with TNBC gemcitabine + carboplatin added pull trastuzumab (Lacnotuzumab, an anti-colony stimulating factor monoclonal antibody) efficacy
.

Lacnotuzumab (Lacnotuzumab, an anti-colony stimulating factor monoclonal antibody)

Female patients with advanced TNBC who have high levels of tumor-associated macrophages and are not suitable for surgery or radiotherapy were recruited and randomly divided into two groups to receive gemcitabine-carboplatin + latuzumab (10 mg/kg·3 weeks) or gemcitabine-carbohydrate Platinum treatment
.

Continue treatment until intolerable toxicity, disease progression, or doctor/patient's decision to terminate treatment

A total of 49 patients were recruited, of which 34 received gemcitabine-carboplatin + latuzumab treatment, and 15 received gemcitabine-carboplatin treatment
.

Due to the rapid development of the treatment field, recruitment was faced with challenges, and recruitment was eventually stopped; therefore, no formal hypothesis testing was performed on the primary endpoint

Event-free survival rate of the two groups

Event-free survival rate of the two groups

The median progression-free survival in the gemcitabine-carboplatin+latuzumab group and gemcitabine-carboplatin group were 5.
6 months (95% CI 4.
47-8.
64) and 5.
5 months (3.
45-7.
46), respectively
.

The median progression-free survival of gemcitabine-carboplatin+latuzumab group and gemcitabine-carboplatin group were 5.
6 months (95% CI 4.
47-8.
64) and 5.
5 months (3.
45-7.
46) gemcitabine-carboplatin, respectively +The median progression-free survival of the latuzumab group and gemcitabine-carboplatin group were 5.
6 months (95% CI 4.
47-8.
64) and 5.
5 months (3.
45-7.
46), respectively

The occurrence of adverse events

The occurrence of adverse events

Hematological adverse events were common in both groups; however, patients treated with latuzumab more frequently experienced elevations in aspartate aminotransferase, alanine aminotransferase, and creatine kinase
.

In summary, the gemcitabine-carboplatin+latuzumab regimen has significantly anti-tumor activity comparable to the gemcitabine-carboplatin regimen, but the tolerance is slightly poor
.

However, the results of this study provide information for further research on the application of targeted colony stimulating factor factors in the treatment of TNBC

The gemcitabine-carboplatin+latuzumab regimen has significantly anti-tumor activity comparable to the gemcitabine-carboplatin regimen, but the tolerability is slightly worse .

Original source:

Sherko Kuemmel, et al.

A Randomized Phase II Study of Anti- CSF-1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple Negative Breast Cancer in this message